RecruitingNCT01670695
A Prospective Cohort Study of IgG4RD in China
Cohort Study of Patients With IgG4-Related Disease
Sponsor
Peking Union Medical College Hospital
Enrollment
1,000 participants
Start Date
Jan 1, 2012
Study Type
OBSERVATIONAL
Conditions
Summary
This is an cohort study to investigate the disease course and treatment response of patients with IgG4-related disease.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria7
- Males and females
- Age 18-75 years old with informed consent
- Patients with IgG4-RD:
- swelling, sclerosing and inflammatory involvement of one or more organ, including sclerosing pancreatitis, sclerosing cholangitis, inflammatory pseudotumors, retroperitoneal or mediastinal fibrosis, interstitial nephritis, hypophysitis, sclerosing dacryoadenitis, sialadenitis, inflammatory aortic aneurysm, lymphadenopathy, or other inflammatory conditions;
- elevated serum IgG4 (>1.35 g/L)
- histopathologic features of fibrosis and/or lymphocytic and polyclonal plasma cell infiltration (and IgG4+ plasma cells on immunohistology when performed);
- exclusion of other diseases.
Exclusion Criteria3
- Females planning to bear a child recently or with childbearing potential
- Concurrent severe and/or uncontrolled and/or unstable diseases
- Patient with malignancy
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT01670695
Related Trials
Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases
NCT062855396 locations
The Investigators Will Evaluate the Diagnostic Performance of [18F]-AlF-FAPI-74 PET/CT in Inflammatory Disorders and Compare it With the Current Gold Standard for Inflammation, FDG PET/CT, in Three Patient Cohort: Patients Presenting With Fever of Unknown Origin, IgG4-RD and AxSpA.
NCT075355541 location
Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
NCT070619383 locations
A Study of Efgartigimod in Patients With IgG4-Related Disease
NCT070253301 location
A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease
NCT070681651 location